Company releases

Investors
Home
Nightingale as an investment
Key strengths
CEO's greetings
Operational environment
Strategy
Dividends policy
Financial information
Key figures
Share and shareholders
Share information
Share monitor
Shareholders
Authorisations
Governance
Governance principles
General Meeting
Annual General Meeting 2021
Board of Directors
Management Team
Remuneration
Risk management
Insider management
Managers' transactions
Auditor
Certified Adviser
Articles of Association
Code of Conduct
Investor relations
Investor calendar
Investor contacts
Disclosure policy
Releases
Company releases
Press releases
Managers' transactions
Reports and presentations
Reports and presentations
IPO
IPO 2021
Investors

Company releases

13/10/2021 Nightingale and Terveystalo launch a new well-being membership

1/10/2021 Notice to the Annual General Meeting of Nightingale Health Plc

1/10/2021 Nightingale's Annual Report for financial year 2020–2021 published

15/9/2021 Nightingale Health Plc Financial Statements Release 1 July 2020 – 30 June 2021

30/8/2021 Jeffrey Barrett appointed as Chief Scientific Officer of Nightingale Health Plc

9/7/2021 Nightingale Health acquires German digital health company Yolife GmbH

1/7/2021 Nightingale Health quarterly summary of achieved key milestones and reiteration of near-term business targets

29/6/2021 Nightingale secures global scalability of its at-home solution by partnering with at-home blood collection device manufacturer Weavr with new commercial terms and minority investment

23/6/2021 Nightingale successfully completes the first phase of its at-home blood testing pilot

4/5/2021 Nightingale restructures its Management Team and established strategic partnership with Reaktor

29/4/2021 Nightingale Health signed service agreement for health and well-being services in Japan

22/4/2021 Nightingale Health Plc and Terveystalo have entered into strategic partnership agreement

9/4/2021 Nightingale Health Plc’s subsidiary received clinical laboratory certification in Japan

31/3/2021 The cancellation of Nightingale Health Plc’s treasury shares entered in the Trade Register

25/3/2021 Nightingale Health Plc’s ten largest shareholders after the completion of the initial public offering

23/3/2021 Stabilisation measures taken and the end of the stabilisation period; the Board of Directors has resolved on the cancellation of treasury shares

18/3/2021 The IPO of Nightingale has been oversubscribed and the listing will be completed as planned – trading in the series B shares is expected to commence on 19 March 2021

16/3/2021 Public offering of Nightingale has been oversubscribed and therefore the subscription period has been discontinued

15/3/2021 Nightingale Health Plc comments on the media coverage on its initial public offering

8/3/2021 Nightingale announces a fixed subscription price and publishes a prospectus for its contemplated IPO and listing of its series B shares on Nasdaq First North Growth Market Finland

8/3/2021 Nightingale has applied for its series B shares to be listed on Nasdaq First North Growth Market Finland and commences the initial public offering

For individuals
Blood test and app
Blog
FAQ
Buy
Sign in
For business
Nightingale for business
Health initiatives
For investors
Investor pages
Nightingale as an investment
Financial information
Share and shareholders
Governance
Investor relations
Releases
Reports and presentations
IPO
Suomeksi
For research
Blood Biomarker Analysis
Biomarkers
Publications
About us
Company
Technology
News
Careers
Contact
Get our newsletter
Interested in getting the latest news about Nightingale? Subscribe to our newsletter.
Nightingale Health Oyj
Mannerheimintie 164a, 00300 Helsinki, Finland
Contact →
© 2020 Nightingale HealthTerms and policies